HypertensionPHOP-HTNCT06160921
Prognostic Model of Hypertension
An observational study of Hypertension, run by Xinjiang Medical University at 1 site in China.
Trial summary
The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Hypertension
- What is being tested?
- Standard therapy
- How many people
- 50,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2020to 1 Jan 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University
Who may be able to join
- A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University
Who cannot join
- Patients with secondary hypertension, patients with liver and kidney dysfunction,
- patients with mental disorders, and patients who are unwilling to participate in this trial
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The First Affiliated Hospital of Xinjiang Medicial University
Ürümqi, Xinjiang, 830000
Xiang xie, PHD, 15099169036, xiangxie999@sina.com
About this study
The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.
Read the detailed description
The aim of the study is to establish a platform for monitoring, clinical research and translational medicine in Xinjiang, which aims to provide a basis for future quality improvement and research, and to promote efforts to improve the prognosis of patients with hypertension, and to translate research into improved care for patients, thereby reducing Morbidity and mortality associated with hypertension.
- Conditions
- Hypertension
- Being tested
- Standard therapy
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard therapyOther
Individualized blood pressure reduction program
| Study group | Role | What they receive |
|---|---|---|
| 2 | Not described Receives: Other: Standard therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Resistant hypertension
Measured: 10 years of follow-up Resistant hypertension occurred during this period
Death (all-cause mortality, mortality from hypertension complications)
Measured: 10 years of follow-up deaths occurred during this period
Secondary outcomes (1)
Major adverse cardiovascular events
Measured: 10 years of follow-up deaths occurred during this period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Dec 2023
- Study start1 Jan 2020
- Primary completion1 Jan 2030 (estimated)
- Study completion1 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 50,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xinjiang Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiang Xie, Xinjiang Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06160921
- Sponsor's protocol ID
- 20190818
- Acronym
- PHOP-HT
- Status last verified
- Mar 2024
- First submitted
- 29 Nov 2023
- Last updated
- 28 Mar 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Model of Hypertension
- ClinicalTrials.gov ID
- NCT06160921
- Acronym / sponsor ID
- PHOP-HT / 20190818
- Conditions
- Hypertension
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50,000 participants (estimated)
- Lead sponsor
- Xinjiang Medical UniversityUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 1 Jan 2030 (estimated)
- Study completion
- 1 Jan 2030 (estimated)
- First posted
- 7 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.
Detailed description
The aim of the study is to establish a platform for monitoring, clinical research and translational medicine in Xinjiang, which aims to provide a basis for future quality improvement and research, and to promote efforts to improve the prognosis of patients with hypertension, and to translate research into improved care for patients, thereby reducing Morbidity and mortality associated with hypertension.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 2 | – | Other: Standard therapy |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University
Key inclusion criteria (1 listed)
- A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University
Key exclusion criteria (2 listed)
- Patients with secondary hypertension, patients with liver and kidney dysfunction,
- patients with mental disorders, and patients who are unwilling to participate in this trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard therapyIndividualized blood pressure reduction program | Other | 2 |
Primary outcome
Resistant hypertension
Time frame: 10 years of follow-up Resistant hypertension occurred during this period
Death (all-cause mortality, mortality from hypertension complications)
Time frame: 10 years of follow-up deaths occurred during this period
1 secondary outcome
Major adverse cardiovascular events
Time frame: 10 years of follow-up deaths occurred during this period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Mar 2024.
- Individual participant dataSharing planned: No
Related trials for Hypertension
Not yet recruiting
PAUL® Glaucoma Implant Safety and Effectiveness Study
Refractory Glaucoma
RecruitingObservational study
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Asthma Bronchial
RecruitingObservational study
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Intracerebral Hemorrhage, Stroke
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Recruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Fluid Accumulation, Blood Pressure Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension, run by Xinjiang Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiang Xie, Phd (15099169036, xiangxie999@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Resistant hypertension (time frame: 10 years of follow-up Resistant hypertension occurred during this period). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2024.